T. Rowe Price Group

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2019, the company utilizes artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By employing machine learning techniques, Delfi Diagnostics develops high-precision, non-invasive tests that aim to detect cancer at a stage when it is most treatable. Their technology enables healthcare professionals to recognize previously unrecognized cancer-associated cell-free DNA fragments, facilitating timely and effective treatment options for patients.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2019, the company utilizes artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By employing machine learning techniques, Delfi Diagnostics develops high-precision, non-invasive tests that aim to detect cancer at a stage when it is most treatable. Their technology enables healthcare professionals to recognize previously unrecognized cancer-associated cell-free DNA fragments, facilitating timely and effective treatment options for patients.

Xometry Inc. is a provider of on-demand manufacturing services, specializing in various advanced production techniques, including 3D printing, CNC machining, injection molding, and urethane casting. Established in 2013 and headquartered in Gaithersburg, Maryland, with an additional office in Bethesda, the company operates an AI-enabled marketplace that facilitates the efficient sourcing of custom-manufactured parts and assemblies. Xometry's diverse offerings include rapid prototyping, volume production, mechanical assembly, and aftermarket solutions, catering to a wide range of clients, including engineers, product designers, and business owners. The company has a strategic partnership with Roush Yates Manufacturing Solutions, further enhancing its capabilities in the manufacturing sector. Xometry is organized into U.S. and International segments, with the majority of its revenue generated from the U.S. market.

Thrive Earlier Detection Corp. is a healthcare company that specializes in developing advanced blood testing technologies for early cancer detection. Its flagship product, CancerSEEK, is a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma, allowing for the identification of various cancers at their nascent stages, often before symptoms manifest. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate cancer screening into standard medical practice. The company leverages real-world data and machine learning to enhance the accuracy of cancer detection, facilitate follow-up testing, and streamline the transition to oncological care. Thrive operates as a subsidiary of Exact Sciences Corporation and has received investments from notable firms including Third Rock Ventures and Section 32.

Xometry Inc. is a provider of on-demand manufacturing services, specializing in various advanced production techniques, including 3D printing, CNC machining, injection molding, and urethane casting. Established in 2013 and headquartered in Gaithersburg, Maryland, with an additional office in Bethesda, the company operates an AI-enabled marketplace that facilitates the efficient sourcing of custom-manufactured parts and assemblies. Xometry's diverse offerings include rapid prototyping, volume production, mechanical assembly, and aftermarket solutions, catering to a wide range of clients, including engineers, product designers, and business owners. The company has a strategic partnership with Roush Yates Manufacturing Solutions, further enhancing its capabilities in the manufacturing sector. Xometry is organized into U.S. and International segments, with the majority of its revenue generated from the U.S. market.